Other investigators have shown that a DC i.t. treatment approach in combination with local radiotherapy can increase the migration capacity of i.t. injected DC as well as control the growth of treated primary and untreated distant tumors by mediating the frequency of circulatory tumor antigen specific CD8+ T cells.32 We observed generation of systemic antitumor immunity following combined treatment with HER2-DC i.t. and anti-HER2 antibodies in the HER2pos BC model used, which was evidenced by attenuated growth of untreated distant tumors. The gene discussed is ERBB2; the disease is breast cancer.